Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States
Authors' conclusion
Early real-world MM780G use in the United States demonstrated a high percentage of time in range with low time above and below range. These outcomes are similar to those observed for real-world MM780G use in other countries.
Study context
- Population
- Individuals with T1D using the MM780G with Guardian 4 sensor in the US, CareLink data uploaded from launch to August 22, 2023
- Exposure
- Overall MM780G users vs those using recommended settings; MM770G users before vs after upgrade to MM780G
- Overalln = 7,499reference
- MM770Gn = 3,851
- Outcome
- 24-h CGM metrics
Methodological detailsaggregated CareLink personal data
- Aggregated CareLink personal data
Main finding
As reported in the abstract
| Group | Value | %TITR (70-140 mg/dL) |
|---|---|---|
| Recommended settings | mean 81.4% | 56.4% |
Recommended settings
Valuemean 81.4%
%TITR (70-140 mg/dL)56.4%
- Recommended settings use
- 22% of all users
Observational data: associations, not effects.
Further findings
MM770G to MM780G upgrade: %TIR, %TITR, %TAR
- %TIR increased (MM770G to MM780G)
- 73.2% to 78.3%
- %TITR increased
- 45.8% to 52.6%
- %TAR reduced
- 25.1% to 20.2%
- P < 0.001, for all three
Closed-loop (CL) exits/week
- CL exits/week averaged, all MM780G users
- <1
Original publication
Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States. Diabetes Technol Ther. Published 5 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →